Literature DB >> 27448187

Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model.

Yiming Chen1, Sattva Neelapu1, Lei Feng2, Weiqi Bi1, Tian-Hui Yang3, Michael Wang1, Michelle A Fanale1, Jason R Westin1, Fredrick B Hagemeister1, Luis E Fayad1, Jorge E Romaguera1, Felipe Samaniego1, Francesco Turturro1, Nathan H Fowler1, Peter McLaughlin1, Fernando Cabanillas1, Yasuhiro Oki1, Loretta J Nastoupil1, Alma Rodriguez4.   

Abstract

There are limited reports that baseline peripheral absolute neutrophil count (ANC), absolute monocyte count (AMC), absolute lymphocyte count (ALC) and serum β2-microglobulin level independently predict survival in patients with diffuse large B-cell lymphoma (DLBCL). To confirm these findings, we analysed these parameters together with components of the International Prognostic Index (IPI) in patients with newly-diagnosed DLBCL. We evaluated baseline clinical features for their ability to predict survival in 817 newly diagnosed, previously untreated patients with DLBCL who received frontline treatments between October 2001 and December 2011. The median age at diagnosis was 58 years. Multivariate analysis identified elevated baseline ANC (P = 0·036), AMC (P = 0·028) and serum β2-microglobulin level (P < 0·001), poor performance status (P < 0·001) and high number of extranodal disease sites (P = 0·0497) as independent unfavourable predictors of OS; serum β2-microglobulin level was the strongest predictor of survival outcomes among all the parameters. High baseline serum β2-microglobulin, ANC and AMC levels are independent prognostic factors for short overall survival in patients with newly diagnosed DLBCL. Our new model, based on the above five parameters, better stratifies patients into various risk categories than the IPI for newly diagnosed DLBCL.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  absolute monocyte counts; absolute neutrophil counts; diffuse large B-cell lymphoma; prognosis; serum β2-microglobulin level

Mesh:

Substances:

Year:  2016        PMID: 27448187     DOI: 10.1111/bjh.14237

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study.

Authors:  Jun Cai; Xiaopeng Tian; Shuyun Ma; Liye Zhong; Wenyu Li; Liang Wang; Linlang Guo; Zhihua Li; Yudan Wu; Guangzheng Zhong; Huiqiang Huang; Zhongjun Xia; Yi Xia; Panpan Liu; Ning Su; Yu Fang; Yuchen Zhang; Qingqing Cai
Journal:  Br J Cancer       Date:  2021-05-19       Impact factor: 7.640

2.  Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment.

Authors:  Feng Tang; Yu-Hang Zhao; Qing Zhang; Wei Wei; Su-Fang Tian; Chen Li; Jie Yao; Ze-Fen Wang; Zhi-Qiang Li
Journal:  CNS Neurosci Ther       Date:  2021-05-07       Impact factor: 5.243

3.  Monocytosis as a prognostic factor for survival in stage IB and IIA cervical cancer.

Authors:  Wan Kyu Eo; Byung Su Kwon; Ki Hyung Kim; Heung Yeol Kim; Hong-Bae Kim; Suk Bong Koh; Sungwook Chun; Yong Il Ji; Ji Young Lee; Jeong Namkung; Sanghoon Kwon
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

4.  Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era.

Authors:  Antonio Gutierrez; Leyre Bento; Antonio Diaz-Lopez; Gilberto Barranco; Marta Garcia-Recio; Armando Lopez-Guillermo; Ivan Dlouhy; Jordina Rovira; Mario Rodriguez; Jose María Sanchez Pina; Monica Baile; Alejandro Martín; Silvana Novelli; Juan-Manuel Sancho; Olga García; Antonio Salar; Mariana Bastos-Oreiro; Mª José Rodriguez-Salazar; Ruben Fernandez; Fatima de la Cruz; Jose Antonio Queizan; Sonia González de Villambrosia; Raul Cordoba; Andres López; Hugo Luzardo; Daniel García; Jordi Sastre-Serra; Juan Fernando Garcia; Carlos Montalban; Fernando Cabanillas; Jose Rodríguez
Journal:  Eur J Haematol       Date:  2020-02-18       Impact factor: 2.997

Review 5.  Statistical Challenges in Development of Prognostic Models in Diffuse Large B-Cell Lymphoma: Comparison Between Existing Models - A Systematic Review.

Authors:  Jelena Jelicic; Thomas Stauffer Larsen; Henrik Frederiksen; Bosko Andjelic; Milos Maksimovic; Zoran Bukumiric
Journal:  Clin Epidemiol       Date:  2020-05-27       Impact factor: 4.790

6.  Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count.

Authors:  Yan-Li Li; Zhi-Hu Shi; Xian Wang; Kang-Sheng Gu; Zhi-Min Zhai
Journal:  BMC Cancer       Date:  2019-11-06       Impact factor: 4.430

7.  Combined Diagnostic Significance of Preoperative Serum β2-Microglobulin and Routine Blood Test in Patients with High-grade Glioma and Solitary Brain Metastasis.

Authors:  Liwen Li; Xiaomin Bu; Bin Wu; Shuyuan Zhang; Kai Jin; Liang Xia; Caixing Sun
Journal:  Cancer Manag Res       Date:  2020-11-17       Impact factor: 3.989

8.  Clinicopathological characteristics and prognostic factors of primary pulmonary lymphoma.

Authors:  Huayu He; Fengwei Tan; Qi Xue; Lei Liu; Yue Peng; Guangyu Bai; Moyan Zhang; Shugeng Gao
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

9.  The international staging system improves the IPI risk stratification in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Xiaolei Wei; Xiaoxiao Hao; Lizhi Zhou; Qi Wei; Yuankun Zhang; Weimin Huang; Jialin Song; Ru Feng; Yongqiang Wei
Journal:  Sci Rep       Date:  2017-10-19       Impact factor: 4.379

10.  Impact of Qi-Invigorating Traditional Chinese Medicines on Diffuse Large B Cell Lymphoma Based on Network Pharmacology and Experimental Validation.

Authors:  Qian Huang; Jinkun Lin; Surong Huang; Jianzhen Shen
Journal:  Front Pharmacol       Date:  2021-12-09       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.